SRT 1720 Hydrochloride

目錄號：S1129 Purity: 99.61%

SRT1720 HCl是一種選擇性的SIRT1激活劑，無細胞試驗中EC50為0.16 μM，對SIRT2和SIRT3的作用弱230倍以上。SRT1720 還可誘導自噬。

SRT 1720 Hydrochloride Chemical Structure

CAS: 1001645-58-4

規(guī)格	價格	庫存
10mM (1mL in DMSO)	1960.55	現貨
5mg	1400.82	現貨
50mg	7964.73	現貨
1g	31900	現貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產品質控

批次：純度： 99.61%

99.61

常與SRT 1720 Hydrochloride一起在實驗中被使用的化合物

Selisistat (EX-527)

SRT1720增加Pgrcre/+Rosa26mTmG/+小鼠的子宮內膜異位病變，而Selisistat顯著減少子宮內膜異位病變的數量。

Resveratrol (trans-Resveratrol)

SRT1720增強依托泊苷和長春新堿誘導的細胞死亡，而Resveratrol則抑制ES細胞中的細胞死亡。

Quercetin (Sophoretin)

Quercetin在對抗D-GalN/LPS對雄性Wistar大鼠的細胞毒性作用方面比SRT1720更有效。

Astragaloside IV

SRT1720 HCl和Astragaloside IV在calpain-1敲除中對血管內皮功能障礙(VED)表現出相似的作用。

MDL-28170

SRT1720 HCl和MDL-28170治療可恢復人冠狀動脈內皮細胞(HCAEC)中線粒體ROS水平的增加和膜電位的降低。

SRT 1720 Hydrochloride相關產品

相關靶點	SIRT1 SIRT2 SIRT3 SIRT6 SIRT5	點擊展開
相關產品	Selisistat (EX-527) Sirtinol Fisetin 3-TYP AGK2 SRT2104 (GSK2245840) OSS_128167 SirReal2 SRT2183 Thiomyristoyl Salvianolic acid B NRD167 SRT3025 HCl AK 7 Salermide UBCS039 CAY10602 Inauhzin SIRT1 Antibody (Mouse mAb) [N11B23] Tenovin-3 SIRT7 inhibitor 97491	點擊展開
相關化合物庫	激酶抑制劑庫 FDA藥物庫天然產物庫已知活性藥物庫-I 高選擇性抑制劑庫	點擊展開

細胞實驗數據示例

細胞系	實驗類型	給藥濃度	孵育時間	活性描述	文獻信息(PMID)
MC3T3-E1	Function Assay	10 μM	60 min?	attenuates the FGF-2-induced osteoprotegerin mRNA expression	25290095
MC3T3-E1	Function Assay	10 μM	60 min?	suppresses the FGF-2-stimulated osteoprotegerin release	25290095
MDA-MB-231	Function Assay	5 μM	16 h	induces lysosomal membrane permeabilization	25411356
MDA-MB-231	Function Assay	5 μM	8 h	increases the number of acidic vesicular organelles	25411356
Neu	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
HCT116	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
A459	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
BT20	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
HS578T	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
SUM149	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
MDA-MB-231	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
SKBR3	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
T47D	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
MCF-7	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
MCF10A	Growth Inhibition Assay	0-20 μM	24 h	reduces cell viability dose dependently	25411356
RAW264.7	Function Assay	1 μM	6 h	upregulates the reduced SIRT1 protein or mRNA levels by high glucose	25793995
NRK-49F	Function Assay	0–2?μM	36 h	enhances STAT3 phosphorylation	26022003
NRK-49F	Function Assay	0–2?μM	36 h	enhances phosphorylation of EGFR and PDGFRβ?	26022003
NRK-49F	Function Assay	0–2?μM	36 h	increases expression of α-SMA and fibronectin dose dependently	26022003
SK-N-MC?	Function Assay	3 μM	0-24 h	activates caspase 3/7	26055805
SK-ES-1	Function Assay	10 μM	0-24 h	activates caspase 3/7	26055805
WE-68	Function Assay	20 μM	0-24 h	activates caspase 3/7	26055805
SK-N-MC?	Apoptosis Assay	0-2.5 μM	24 h	induces cell death in dose dependently	26055805
SK-ES-1	Apoptosis Assay	0-10 μM	24 h	induces cell death in dose dependently	26055805
WE-68	Apoptosis Assay	0-24 μM	24 h	induces cell death in dose dependently	26055805
MC3T3-E1	Function Assay	20 μM	1 h	suppresses the TGF-β-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK	26136978
MC3T3-E1	Function Assay	10 μM?	12 h	reduces the VEGF mRNA expression levels stimulated by TGF-β	26136978
MC3T3-E1	Function Assay	10 μM?	1 h	reduces the TGF-β-stimulated VEGF release in dose- and time-dependent manner?	26136978
CACs?	Function Assay	4?μM	30?min	induces acute SIRT1 activation?	26254104
MC3T3-E1	Function Assay	10 μM	60 min?	attenuates the FGF-2-induced osteoprotegerin mRNA expression	25290095
MC3T3-E1	Function Assay	10 μM	60 min?	suppresses the BMP-4-stimulated VEGF release	24435444
MC3T3-E1	Function Assay	10 μM	60 min?	suppresses the PGF2α-stimulated OPG release	24333336
MC3T3-E1	Function Assay	10 μM	60 min?	reduces the PGF2α-stimulated phosphorylation of p44/p42 MAP kinase	24333336
MC3T3-E1	Function Assay	10 μM	60 min?	attenuates the PGF2α-induced phosphorylation of both MEK1/2 and Raf-1	24333336
RPE	Cell Viability Assay	5 μM	1 h	attenuates OAβ-induced decrease of cell viability	24036938
9607	Cell Viability Assay	1 μM	36 h	increases the cell viability compared with melatonin alone	23726949
9607	Function Assay	1 μM	36 h	increases SIRT1 and decreased acetylated-p53 expression	23726949
RPMI.8226	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
U266	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
MM.1S	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
KMS12	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
LR5	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
MM.1R	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
Ina6	Cell Viability Assay	7/10 μM	24 h	decreases viability concentration dependently	21950728
RPMI-8226	Apoptosis Assay	7/10 μM	24 h	induces a significant increase in the Annexin V+/PI??apoptosis	21950728
MM.1R?	Apoptosis Assay	7/10 μM	24 h	induces a significant increase in the Annexin V+/PI??apoptosis	21950728
H411EC3	Function Assay	50/100 nM	6 h	increases SIRT1 activity in the presence of TSA, PEPCK activity, mRNA levels of Pck1 and Pgc1α, and elevating glucose production	21212096
hepatocytes	Function Assay	10 nM	6 h	increases SIRT1 activity in the presence of TSA, PEPCK activity, mRNA levels of Pck1 and Pgc1α, and elevating glucose production	21212096
hepatocytes	Function Assay	10 nM	6 h	increases Hmgcr?and?Acc?gene expression	21212096
U2OS	Function assay	0.10 uM		Activation of SIRT1 in human U2OS cells assessed as decrease in p53 deacetylation level at 0.10 uM	18046409
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
Rh30	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
點擊查看更多細胞系數據

生物活性

產品描述

SRT1720 HCl是一種選擇性的SIRT1激活劑，無細胞試驗中EC50為0.16 μM，對SIRT2和SIRT3的作用弱230倍以上。SRT1720 還可誘導自噬。

靶點

SIRT1
(Cell-free assay)

0.16 μM(EC50)

體外研究(In Vitro)
體外研究活性	SRT1720抗最近的乙?；竿滴颯IRT2 (EC1.5為37 μM)和SIRT3 (EC1.5 > 300 μM)的最大激活率達781%。SRT1720在氨基末端催化區(qū)的變構位點結合到SIRT1酶-肽底物復合物上，降低乙?；孜锏拿资铣抵?。用SRT1720處理一周后，飼喂的葡萄糖水平降低，處理三周后，飼喂的葡萄糖水平進一步降低，持續(xù)處理10周。SRT1720對用無糖食物喂養(yǎng)的鼠沒有作用效果，顯示出藥理學SIRT1的激活不會產生低血糖。用SRT1720處理4周，明顯降低高胰島素血癥，使升高的胰島素水平恢部分復正常SRT1720處理腓腸肌，通過測定檸檬酸合酶活性發(fā)現線粒體各項能力上升15%。高濃度 SRT1720 (15 μM)誘導正常細胞活力輕微下降，約10-20%。SRT1720明顯抑制VEGF依賴的 MM 細胞遷移。
激酶實驗	SIRT1熒光偏振實驗
激酶實驗	在SIRT1 FP試驗中，使用從p53序列中得到的含20個氨基酸的肽段 (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly-Lys(MR121或 Tamra)-Glu-Glu-NH2)。肽段N端與生物素相連，C端用熒光標記修飾。監(jiān)測酶活的反應是酶活偶聯反應，第一步反應為SIRT1催化的脫乙酰反應，第二步反應為在新暴露的賴氨酸殘基處進行胰蛋白酶催化的分裂。為了突出底物和產物的多種區(qū)別，加入鏈酶親和素，反應終止。FP測試的敏感性可用來鑒定SRT1720。進行熒光偏振反應環(huán)境如下：0.5 μM 肽底物, 150 μM βNAD⁺, 0-10 nM SIRT1, 25 mM Tris-醋酸鹽（pH 為8）, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl₂, 5 mM DTT, 0.025% BSA, 及0.15 mM煙堿。反應在37^oC溫育，加入煙堿終止反應，加入胰蛋白酶分裂脫乙酰底物。加入鏈酶親和素在37^oC溫育。在650 nm 和680nm 處測定熒光偏振。
細胞實驗	細胞系	人類血管內皮細胞(HUVECs)
	濃度	5 μM
	孵育時間	2小時
	方法	使用Transwell遷移實驗測定遷移率。通過基底膜的毛細血管樣管結構形成試劑盒檢測體外血管生成。用于內皮血管生成實驗，從Clonetics獲得的人類血管內皮細胞（HUVEC），保存在含5% FBS的內皮細胞生長培養(yǎng)基中。使用臺盼藍拒染法測定HUVEC細胞活力，觀察到用SRT1720處理的細胞死亡率小于5%。
實驗圖片	檢測方法	檢測指標	實驗圖片	PMID
	Western blot	感谢您访问我们的网站，您可能还对以下资源感兴趣：一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线桃源县\| 思茅市\| 英吉沙县\| 资溪县\| 乐亭县\| 成安县\| 德安县\| 易门县\| 凤翔县\| 通山县\| 贵溪市\| 云林县\| 辽源市\| 浪卡子县\| 敦煌市\| 苏尼特左旗\| 竹溪县\| 宁明县\| 永丰县\| 兰州市\| 丹江口市\| 凤城市\| 岚皋县\| 芜湖县\| 额尔古纳市\| 无为县\| 彝良县\| 凌海市\| 双桥区\| 深水埗区\| 铜陵市\| 璧山县\| 商洛市\| 平和县\| 揭东县\| 双辽市\| 阳东县\| 阜平县\| 江都市\| 昭苏县\| 德州市\|

一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线